Powles Highlights “Transformative” Benefit of EV Plus Pembro While Sharing Long-Term Data for EV-302
Enfortumab vedotin and pembrolizumab combination offers transformative benefits, doubling median progression-free and overall survival in advanced urothelial carcinoma. The EV-302 trial showed a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback